A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

Summary

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge

Timeline

Start

2025-04-14

Primary completion

2026-05-20

Completion

2027-02

Outcome

Met primary endpoint

release “Emerge met its primary endpoint” definiumtx.com ↗

release “Met the primary endpoint and all key secondary efficacy endpoints with a high degree of statistical significance.” definiumtx.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DT120	Unknown	100 ug	Oral

Indications